At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
MK0826, ertapenem sodium / Duration of Treatment - 24 weeks +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.
In Brief
A Phase 3 clinical trial evaluating MK0826, ertapenem sodium / Duration of Treatment - 24 weeks and Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks for Foot Infections in Diabetic Patients. Completed.
Detailed Summary
This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFoot Infections in Diabetic Patients
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2001
Primary CompletionApr 2004
First PostedSep 2005
TodayJul 2026
First PostedSep 29, 2005
Enrollment StartApr 1, 2001
Primary CompletionApr 1, 2004
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.8 years ago
Interventions
MK0826, ertapenem sodium / Duration of Treatment - 24 weeksdrug
Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeksdrug